MIRALUMA DIN 02327929
Health Canada record
| Active ingredient(s) | TETRAKIS [CU(MIBI)4]BF4 1 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | SCHEDULE C |
| Class | Radiopharmaceutical |
| ATC | |
| Original market date | |
| Current status date | 15-Mar-2017 |
| Source | Health Canada DPD |
Establishment licence of the holder
Lantheus MI Canada Inc — licence 101647, currently licensed, last inspection rating C (2023-05-03).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TETRAKIS [CU(MIBI)4]BF4
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02328003 | CARDIOLITE | LANTHEUS MI CANADA INC | Powder For Solution | TETRAKIS [CU(MIBI)4]BF4 1 MG | Marketed |
| 02327732 | DRAXIMAGE SESTAMIBI | JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA | Powder For Solution | TETRAKIS [CU(MIBI)4]BF4 1 MG | Marketed |
| 02329794 | KIT FOR THE PREPARATION OF TECHNETIUM TC 99M SESTAMIBI INJECTION | CURIUM CANADA INC | Kit; Powder For Solution | TETRAKIS [CU(MIBI)4]BF4 1 MG | Marketed |